CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total		Common Stock	Additional Paid-In Capital		Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total UpHealth, Inc. Stockholders’ Equity	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[1],[2]						0
Beginning balance (in shares) at Dec. 31, 2020	[1],[2]			7,002
Beginning balance at Dec. 31, 2020	[1],[2]	$ 220,721		$ 1	$ 222,906		$ 0	$ (2,186)	$ 0	$ 220,721	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to consummate business combinations (in shares)	[1],[2]			875
Issuance of common stock to consummate business combinations	[1],[2]	104,798		$ 0	87,409					87,409	17,389
Net income (loss)		(3,027)						(2,949)		(2,949)	(78)
Foreign currency translation adjustments		(1,159)							(1,159)	(1,159)
Ending balance (in shares) at Mar. 31, 2021	[1],[2]			7,877
Ending balance at Mar. 31, 2021	[1],[2]	321,333		$ 1	310,315		0	(5,135)	(1,159)	304,022	17,311
Beginning balance (in shares) at Dec. 31, 2020	[1],[2]			7,002
Beginning balance at Dec. 31, 2020	[1],[2]	220,721		$ 1	222,906		0	(2,186)	0	220,721	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(4,829)
Foreign currency translation adjustments		(3,459)
Ending balance (in shares) at Sep. 30, 2021	[2]			11,780
Ending balance at Sep. 30, 2021	[2]	626,549		$ 1	621,871		$ 0	(7,161)	(3,459)	611,252	15,297
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[1],[2]						0
Beginning balance (in shares) at Mar. 31, 2021	[1],[2]			7,877
Beginning balance at Mar. 31, 2021	[1],[2]	321,333		$ 1	310,315		$ 0	(5,135)	(1,159)	304,022	17,311
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to consummate business combinations (in shares)	[1],[2]			2,616
Issuance of common stock to consummate business combinations	[1],[2]	241,348		$ 0	243,587					243,587	(2,239)
Merger recapitalization (in shares)	[1],[2]			947
Merger recapitalization	[1],[2]	54,605		$ 0	54,605					54,605
PIPE common stock issuance (in shares)	[2]			300
PIPE common stock issuance	[2]	27,079			27,079					27,079
Forward share repurchase agreement	[2]	(17,000)			(17,000)					(17,000)
Issuance of common stock for debt conversion (in shares)	[1],[2]			20
Issuance of common stock for debt conversion	[1],[2]	1,879			1,879					1,879
Net income (loss)		(32,789)						(32,783)		(32,783)	(6)
Foreign currency translation adjustments		(2,319)							(2,319)	(2,319)
Ending balance (in shares) at Jun. 30, 2021	[2]			11,760
Ending balance at Jun. 30, 2021	[2]	594,136		$ 1	620,465		$ 0	(37,918)	(3,478)	579,070	15,066
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[2]						0
Purchase consideration adjustment		677			677					677
Exercise of stock option, net (in shares)	[2]			20
Exercise of stock options, net		319	[2]		319	[2]				319
Stock-based compensation		410			410					410
Net income (loss)		30,988						30,757		30,757	231
Foreign currency translation adjustments		19							19	19
Ending balance (in shares) at Sep. 30, 2021	[2]			11,780
Ending balance at Sep. 30, 2021	[2]	626,549		$ 1	621,871		$ 0	(7,161)	(3,459)	611,252	15,297
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[2]						0
Beginning balance (in shares)	[3]						0
Beginning balance (in shares) at Dec. 31, 2021	[3]			14,428
Beginning balance at Dec. 31, 2021	[3]	333,843		$ 1	665,474		$ 0	(343,209)	(3,802)	318,464	15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[3]			37
Equity award activity, net of shares withheld for taxes	[3]	(67)			(67)					(67)
Stock-based compensation		1,374			1,374					1,374
Net income (loss)		(17,705)						(17,445)		(17,445)	(260)
Foreign currency translation adjustments		(1,377)							(1,377)	(1,377)
Ending balance (in shares) at Mar. 31, 2022	[3]			14,465
Ending balance at Mar. 31, 2022	[3]	316,068		$ 1	666,781		0	(360,654)	(5,179)	300,949	15,119
Beginning balance (in shares) at Dec. 31, 2021	[3]			14,428
Beginning balance at Dec. 31, 2021	[3]	333,843		$ 1	665,474		0	(343,209)	(3,802)	318,464	15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Deconsolidation of subsidiary		(14,300)
Net income (loss)		(195,754)
Foreign currency translation adjustments		(3,857)
Ending balance (in shares) at Sep. 30, 2022	[3]			15,006
Ending balance at Sep. 30, 2022	[3]	131,482		$ 2	686,518		$ (17,000)	(538,854)	0	130,666	816
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[3]						0
Beginning balance (in shares) at Mar. 31, 2022	[3]			14,465
Beginning balance at Mar. 31, 2022	[3]	316,068		$ 1	666,781		$ 0	(360,654)	(5,179)	300,949	15,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[3]			390
Equity award activity, net of shares withheld for taxes	[3]	(1,159)			(1,160)					(1,159)
Stock-based compensation		1,088			1,088					1,088
Common stock repurchased in connection with forward share purchase agreement (in shares)	[3]			(170)			170
Common stock repurchased in connection with forward share purchase agreement	[3]	0			17,000		$ (17,000)
Purchase of noncontrolling interest		(139)									(139)
Distribution to noncontrolling interests		(30)									(30)
Net income (loss)		(12,465)						(12,438)		(12,438)	(27)
Foreign currency translation adjustments		(2,480)							(2,480)	(2,480)
Ending balance (in shares) at Jun. 30, 2022	[3]			14,685
Ending balance at Jun. 30, 2022	[3]	300,883		$ 2	683,709		$ (17,000)	(373,092)	(7,659)	285,960	14,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[3]						170
Equity award activity, net of shares withheld for taxes	[3]	(30)			(30)					(30)
Issuance of common stock in connection with 2025 Notes	[3]	713			713					713
Stock-based compensation		2,126			2,126					2,126
Deconsolidation of subsidiary		(6,626)							7,659	7,659	(14,285)
Net income (loss)		(165,584)						(165,762)		(165,762)	178
Foreign currency translation adjustments		0
Ending balance (in shares) at Sep. 30, 2022	[3]			15,006
Ending balance at Sep. 30, 2022	[3]	$ 131,482		$ 2	$ 686,518		$ (17,000)	$ (538,854)	$ 0	$ 130,666	$ 816
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	[3]						170

[1] Amounts as of March 31, 2021 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the accounting for the Business Combinations (as defined below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Business Combinations are computed on the basis of the number of common shares of UpHealth Holdings (accounting acquiror) during those periods multiplied by the exchange ratio established in the stock purchase agreement (1.00 UpHealth Holdings shares converted to 10.28 GigCapital2 shares). Common stock and additional paid-in capital were adjusted accordingly.

[2] Amounts as of September 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

[3] Amounts as of September 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.